Share
Save
Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)
This is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors \>55 years old with chemotherapy \>5 years ago. The overall goal of this study to identify the feasibility and value of risk-guided cardiac rehabilitation (exercise, risk factor modification, and behavioural support) as a component of survivorship care.
Study details:
Participants enrolled in this study will be randomized to cardio-oncology disease management plan ( CO-DMP) that involves the use of surveillance imaging to detect subclinical left ventricular dysfunction (LVD), clinical review to ensure optimal risk factor control and cardio-protection and exercise/sedentariness intervention. The intervention will be delivered over a period of 6 months. Usual care patients will then cross over the CO-DMP for 6 months.
The outcome from this study will show that subclinical LVD is more common among long term cancer survivors, and a CO-DMP is feasible in reducing HF risk factors in this sub group of survivors.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 40 and older
Healthy volunteers accepted : Yes
Gender eligible for study: All
Things to know
Study dates
Study start: 2023-03-30
Primary completion: 2025-12-31
Study completion finish: 2025-12-31
Study type
SCREENING
Phase
NA
Trial ID
NCT04962711
Intervention or treatment
OTHER: Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)
OTHER: Usual care
Conditions
- • Heart Failure
Find a site
Closest Location:
Baker Heart and Diabetes Institute
Research sites nearby
Select from list below to view details:
Baker Heart and Diabetes Institute
Melbourne, Victoria, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Participant Group/Arm | Intervention/Treatment |
---|---|
EXPERIMENTAL: Heart failure intervention ( Cardio-Oncology Disease Management Plan (CO-DMP)
| OTHER: Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)
|
ACTIVE_COMPARATOR: Usual care
| OTHER: Usual care
|
What is the study measuring?
Primary outcome
Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
---|---|---|
Change in exercise capacity | Cardio pulmonary fitness (peak oxygen uptake (VO2 peak)) from baseline to follow up. | Over a period of 12 months |
Secondary outcome
Secondary Outcome Measure | Secondary Outcome Description | Secondary Outcome Time Frame |
---|---|---|
Medication adherence | proportion of ACEi and beta blocker tablets taken | Over a period of 12 months |
Neuromuscular strength | Maximal isometric grip strength (kg) assessed using a digital grip strength dynamometer | Over a period of 12 months |
Endurance | Increase in total exercise duration. | Over a period of 12 months |
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!